Literature DB >> 9626155

Unique 24-hydroxylated metabolites represent a significant pathway of metabolism of vitamin D2 in humans: 24-hydroxyvitamin D2 and 1,24-dihydroxyvitamin D2 detectable in human serum.

E B Mawer1, G Jones, M Davies, P E Still, V Byford, N J Schroeder, H L Makin, C W Bishop, J C Knutson.   

Abstract

We have produced evidence for a new metabolic pathway for vitamin D2 in humans involving the production of 24-hydroxyvitamin D2 (24OHD2) and 1,24-dihydroxyvitamin D2 [1,24-(OH)2D2]. These metabolites were produced after either a single large dose (10(6) IU) of vitamin D2 or repeated daily doses between 10(3) and 5 x 10(4) IU. We developed assay systems for the metabolites in human serum and showed that in some chronically treated patients, the concentration of 1,24-(OH)2D2 equalled that of 1,25-(OH)2D2 at about 100 pmol/L. The metabolites were identified by high performance liquid chromatography with diode array spectrophotometry for 24OHD2 and by high resolution gas chromatography-mass spectrometry for 1,24-(OH)2D2. We show that 1,24-(OH)2D2 synthesis can be stimulated by PTH, indicating a renal origin for this metabolite and postulate that it is formed from 24OHD2, which may be synthesized in liver. We conclude from this study that vitamin D2 gives rise to two biologically active products, 1,24-(OH)2D2 and 1,25-(OH)2D2, and that 1,24-(OH)2D2 could be an attractive naturally occurring analog of 1,25-(OH)2D3 for clinical use.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9626155     DOI: 10.1210/jcem.83.6.4841

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  7 in total

1.  Model-based meta-analysis for development of a population-pharmacokinetic (PPK) model for Vitamin D3 and its 25OHD3 metabolite using both individual and arm-level data.

Authors:  Alanna S Ocampo-Pelland; Marc R Gastonguay; Jonathan F French; Matthew M Riggs
Journal:  J Pharmacokinet Pharmacodyn       Date:  2016-02-12       Impact factor: 2.745

2.  Model-based meta-analysis for comparing Vitamin D2 and D3 parent-metabolite pharmacokinetics.

Authors:  Alanna S Ocampo-Pelland; Marc R Gastonguay; Matthew M Riggs
Journal:  J Pharmacokinet Pharmacodyn       Date:  2017-05-02       Impact factor: 2.745

3.  A phase I study to determine the maximum tolerated dose and safety of oral LR-103 (1α,24(S)Dihydroxyvitamin D2) in patients with advanced cancer.

Authors:  Kari B Wisinski; Wendy M Ledesma; Jill Kolesar; George Wilding; Glenn Liu; Jeffrey Douglas; Anne M Traynor; Mark Albertini; Daniel Mulkerin; Howard H Bailey
Journal:  J Oncol Pharm Pract       Date:  2014-07-01       Impact factor: 1.809

4.  Vitamin D 2 interacts with Human PrP(c) (90-231) and breaks PrP(c) oligomerization in vitro.

Authors:  Midori Suenaga; Yusuke Hiramoto; Yoichi Matsunaga
Journal:  Prion       Date:  2013-07-15       Impact factor: 3.931

5.  Plasma appearance and disappearance of an oral dose of 25-hydroxyvitamin D2 in healthy adults.

Authors:  Kerry S Jones; Inez Schoenmakers; Les J C Bluck; Shujing Ding; Ann Prentice
Journal:  Br J Nutr       Date:  2011-09-07       Impact factor: 3.718

Review 6.  New Vitamin D analogues for osteodystrophy in chronic kidney disease.

Authors:  John Cunningham
Journal:  Pediatr Nephrol       Date:  2004-05-13       Impact factor: 3.714

Review 7.  The serum vitamin D metabolome: What we know and what is still to discover.

Authors:  Robert C Tuckey; Chloe Y S Cheng; Andrzej T Slominski
Journal:  J Steroid Biochem Mol Biol       Date:  2018-09-08       Impact factor: 4.292

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.